No Data
Strong demand for cancer drugs boosts astrazeneca (AZN.US) performance above expectations, raising annual profit growth rate.
Astrazeneca stated that the company is taking China subsidiary seriously; this united kingdom pharmaceutical giant is increasing investment in the usa recently.
AstraZeneca Reports Strong Growth in Q3 2024
Astrazeneca (AZN.US) and Merck (MRK.US) jointly announced the positive top-line results of the KOMET phase 3 clinical trial.
Today, Astrazeneca (AZN.US) and Merck (MRK.US) jointly announced the positive top-line results of the phase 3 KOMET clinical trial.
Express News | AstraZeneca CEO: Not familiar with the details of the investigation of senior executives in China, will continue to invest in China.
AstraZeneca PLC (AZN) Q3 2024 Earnings Call Transcript Summary
AstraZeneca PLC (AZN) Q3 2024 Earnings Call Transcript
No Data
No Data
